drugset
drugset / Trial / NCT02963727

Use of Wharton Jelly Derived Mesenchymal Stem Cells for Knee Osteoarthrosis

NCT02963727 ↗

Phase 1 Unknown 10 enrolled Hanan Jafar
NaSingle-groupOpen-labelTreatment

Summary

Wharton Jelly derived Mesenchymal Stem Cells (WJMSC) will be injected in patients diagnosed with Knee osteoarthrosis

Timeline

Start
2017-01-27
Primary completion
2021-10
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject WJ-MSC Cell therapy 5e+07 cells Other

Indications

osteoarthritis, knee